Drug Profile

Factor X - Meiji Seika Pharma

Alternative Names: Blood coagulation factor X agent - Meiji Seika Pharma; KD-416

Latest Information Update: 17 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Meiji Seika Pharma
Class Antihaemorrhagics; Blood coagulation factors; Coagulants
Mechanism of Action Blood coagulation factor replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Factor X deficiency
New Molecular Entity No

Highest Development Phases

Phase III Factor X deficiency

Most Recent Events

17 Sep 2025 Meiji Seika Pharma plans regulatory approval for factor X after 2027 (Meiji Seika Pharma presentation, June 2024)
01 Sep 2025 Phase-III clinical trials in Factor X deficiency in Japan (Parenteral) (Meiji Seika Pharma, September 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com